<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04374708</url>
  </required_header>
  <id_info>
    <org_study_id>1R01HD087712-01A1</org_study_id>
    <nct_id>NCT04374708</nct_id>
  </id_info>
  <brief_title>Gender Identity and Own Body Perception</brief_title>
  <official_title>Gender Identity and Own Body Perception- Implications for the Neurobiology of Gender Dysphoria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will provide valuable information on the neurobiological underpinning of gender
      dysphoria (GD) and the effects of sex hormones, and promises to uncover functional or
      structural neural patterns that could predict outcome in terms of body image and quality of
      life after cross-sex hormone treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to understand the neurobiology of gender dysphoria (GD) and the
      interactions between cross hormone treatment, the brain, and the body phenotype. The
      investigators also aim to identify pre-treatment neurobiological and other factors to help
      predict body congruence and quality of life outcomes from hormone treatment. There is
      mounting interest in gender identity issues worldwide, as requests for gender-confirming
      treatments have increased in the past 3 decades, and alarmingly high suicide rates have
      recently been reported in those with GD. Despite this, little is known about neurobiological
      or other etiological factors contributing to GD or gender incongruence. This study will
      address a core feature of GD that has been little studied in terms of the neurobiology: the
      incongruence between perception of self and one's own body.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 6, 2020</start_date>
  <completion_date type="Anticipated">August 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>cerebral networks measured by functional magnetic resonance imaging (fMRI) mediating body perception and association with subjective own-body self-incongruence</measure>
    <time_frame>Baseline Visit 2 pre hormone treatment</time_frame>
    <description>Own body perception in relation to functional and structural connection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Morphometric differences by sex, gender identity and sexual orientation</measure>
    <time_frame>Baseline Visit 2 pre hormone treatment</time_frame>
    <description>Cortical thickness, surface area, cortical and subcortical structural volumes and white matter tracts measured by MRI in relation to sex and gender identity and sexual orientation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Brain activation during own body perception</measure>
    <time_frame>Baseline Visit 2 pre hormone treatment</time_frame>
    <description>Images of body morph test presented during fMRI scan</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in cerebral networks measured by functional magnetic resonance imaging (fMRI) mediating body perception and association with subjective own-body self-incongruence</measure>
    <time_frame>Post hormone treatment. Visit 4 last appt. within 2 yrs of Visit 2.</time_frame>
    <description>Own body perception in relation to functional and structural connection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in morphometric differences by sex, gender identity and sexual orientation</measure>
    <time_frame>Post hormone treatment. Visit 4 last appt. within 2 yrs of Visit 2.</time_frame>
    <description>Cortical thickness, surface area, cortical and subcortical structural volumes and white matter tracts measured by MRI in relation to sex and gender identity and sexual orientation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in brain activation during own body perception</measure>
    <time_frame>Post hormone treatment. Visit 4 last appt. within 2 yrs of Visit 2.</time_frame>
    <description>Images of body morph test presented during fMRI scan</description>
  </primary_outcome>
  <number_of_groups>6</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Gender Dysphoria</condition>
  <arm_group>
    <arm_group_label>trans men</arm_group_label>
    <description>fMRI: body morph test and neurocognitive testing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>trans women</arm_group_label>
    <description>fMRI: body morph test and neurocognitive testing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>homosexual cisgender men</arm_group_label>
    <description>fMRI: body morph test and neurocognitive testing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>homosexual cisgender women</arm_group_label>
    <description>fMRI: body morph test and neurocognitive testing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cisgender women</arm_group_label>
    <description>fMRI: body morph test and neurocognitive testing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cisgender men</arm_group_label>
    <description>fMRI: body morph test and neurocognitive testing</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>fMRI</intervention_name>
    <description>fMRI: body morph test and neurocognitive testing</description>
    <arm_group_label>cisgender men</arm_group_label>
    <arm_group_label>cisgender women</arm_group_label>
    <arm_group_label>homosexual cisgender men</arm_group_label>
    <arm_group_label>homosexual cisgender women</arm_group_label>
    <arm_group_label>trans men</arm_group_label>
    <arm_group_label>trans women</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Investigators will enroll 150 participants between the ages of 18 and 40 (25 trans males;
        25 trans females; 25 cis gender females; 25 cis gender males; 25 homosexual males; 25
        homosexual females)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Participants with gender dysphoria (GD)

        Inclusion Criteria:

          -  Females and males from any racial or ethnic background, between the ages of 18 years
             and 40 years.

          -  Participants must meet Diagnostic and Statistical Manual-5 criteria for GD (302.85)

          -  Intelligence quotient (IQ) &gt; 80

        Participants with GD

        Exclusion Criteria:

          -  Previous or on-going sex hormone medication

          -  Previous sex reassignment surgery

          -  Oral contraceptives

          -  Participants with GD are not be taking any other psychotropic medication. (No
             participant will be recommended to discontinue or taper medications for the purpose of
             participating in the study.)

          -  Irregular menstrual cycles

        Control participants

        Inclusion Criteria:

          -  Females and males from any racial or ethnic background, between the ages of 18 and 40.

          -  IQ &gt; 80

        Control participants

        Exclusion Criteria:

          -  Psychiatric medications

          -  A score of â‰¥ 1 standard deviation higher than population norms on the MADRS depression
             or the Hamilton anxiety scale (HAMA)

          -  Sex hormone treatment

          -  Irregular menstrual cycles

        Exclusion criteria for all participants:

          -  Any known chromosomal or hormonal disorder

          -  Current substance abuse or dependence

          -  Current neurological disorder or psychiatric disorder

          -  Pregnancy

          -  Current major medical disorders that may affect cerebral metabolism such as diabetes
             or thyroid disorders

          -  Head trauma associated with loss of consciousness

          -  HIV positive individuals

          -  Individuals with ferromagnetic metal implantations or devices. This includes any
             electronic implants or devices, braces, infusion pumps, aneurysm clips, metal
             fragments or foreign bodies, metal prostheses, joints, rods or plates

          -  Visual acuity worse than 20/35 for each eye as determined by Snellen close vision
             acuity chart. Acuity may be met with corrective lenses
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Courtney Sheen, M.A.</last_name>
    <phone>(310) 206-0468</phone>
    <email>csheen@mednet.ucla.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jamie Feusner, M.D.</last_name>
    <email>jfeusner@mednet.ucla.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Courtney L Sheen, M.A.</last_name>
      <phone>310-206-0468</phone>
      <email>csheen@mednet.ucla.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jamie D Feusner, M.D.</last_name>
      <phone>310 206-4951</phone>
      <email>jfeusner@mednet.ucla.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jamie D Feusner, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 19, 2020</study_first_submitted>
  <study_first_submitted_qc>April 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 5, 2020</study_first_posted>
  <last_update_submitted>April 30, 2020</last_update_submitted>
  <last_update_submitted_qc>April 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Jamie Feusner</investigator_full_name>
    <investigator_title>Professor of Psychiatry and Biobehavioral Sciences</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gender Dysphoria</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

